MBX Biosciences (MBX) Competitors

MBX Biosciences logo
$53.12 -2.82 (-5.04%)
Closing price 04:00 PM Eastern
Extended Trading
$53.12 0.00 (0.00%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MBX vs. CORT, AXSM, LNTH, AMRX, and BLTE

Should you buy MBX Biosciences stock or one of its competitors? MBX Biosciences's main competitors and comparable companies include Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MBX Biosciences compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Corcept Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Corcept Therapeutics has a net margin of 16.53% compared to MBX Biosciences' net margin of 0.00%. Corcept Therapeutics' return on equity of 22.56% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics16.53% 22.56% 17.83%
MBX Biosciences N/A -34.37%-32.72%

In the previous week, MBX Biosciences had 20 more articles in the media than Corcept Therapeutics. MarketBeat recorded 24 mentions for MBX Biosciences and 4 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.60 beat MBX Biosciences' score of 0.41 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MBX Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Corcept Therapeutics presently has a consensus price target of $139.50, indicating a potential upside of 91.25%. MBX Biosciences has a consensus price target of $87.30, indicating a potential upside of 56.06%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than MBX Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79

Corcept Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43
MBX BiosciencesN/AN/A-$86.97M-$3.07N/A

Summary

Corcept Therapeutics beats MBX Biosciences on 11 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Axsome Therapeutics?

MBX Biosciences (NASDAQ:MBX) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, MBX Biosciences had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 24 mentions for MBX Biosciences and 21 mentions for Axsome Therapeutics. MBX Biosciences' average media sentiment score of 0.41 beat Axsome Therapeutics' score of 0.22 indicating that MBX Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Axsome Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

81.5% of Axsome Therapeutics shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MBX Biosciences presently has a consensus price target of $87.30, suggesting a potential upside of 56.06%. Axsome Therapeutics has a consensus price target of $266.21, suggesting a potential upside of 87.88%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than MBX Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86

MBX Biosciences has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -18.18%. MBX Biosciences' return on equity of -34.37% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -34.37% -32.72%
Axsome Therapeutics -18.18%-198.73%-22.03%

MBX Biosciences has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$3.07N/A
Axsome Therapeutics$638.50M11.67-$183.17M-$3.06N/A

Summary

Axsome Therapeutics beats MBX Biosciences on 8 of the 15 factors compared between the two stocks.

How does MBX Biosciences compare to Lantheus?

MBX Biosciences (NASDAQ:MBX) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

MBX Biosciences presently has a consensus target price of $87.30, indicating a potential upside of 56.06%. Lantheus has a consensus target price of $107.44, indicating a potential upside of 5.76%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe MBX Biosciences is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

Lantheus has a net margin of 17.28% compared to MBX Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.26% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -34.37% -32.72%
Lantheus 17.28%29.26%15.40%

MBX Biosciences has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Lantheus has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$3.07N/A
Lantheus$1.54B4.31$233.56M$4.0625.02

In the previous week, MBX Biosciences had 18 more articles in the media than Lantheus. MarketBeat recorded 24 mentions for MBX Biosciences and 6 mentions for Lantheus. Lantheus' average media sentiment score of 0.87 beat MBX Biosciences' score of 0.41 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lantheus
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Lantheus beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Amneal Pharmaceuticals?

MBX Biosciences (NASDAQ:MBX) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MBX Biosciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 4.17% compared to MBX Biosciences' net margin of 0.00%. Amneal Pharmaceuticals' return on equity of 283.50% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -34.37% -32.72%
Amneal Pharmaceuticals 4.17%283.50%7.79%

Amneal Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$3.07N/A
Amneal Pharmaceuticals$3.02B2.47$72.06M$0.4250.90

In the previous week, MBX Biosciences had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 24 mentions for MBX Biosciences and 7 mentions for Amneal Pharmaceuticals. MBX Biosciences' average media sentiment score of 0.41 beat Amneal Pharmaceuticals' score of 0.38 indicating that MBX Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amneal Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

MBX Biosciences currently has a consensus price target of $87.30, indicating a potential upside of 56.06%. Amneal Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 7.58%. Given MBX Biosciences' higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Amneal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79
Amneal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Amneal Pharmaceuticals beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Belite Bio currently has a consensus target price of $226.27, suggesting a potential upside of 37.68%. MBX Biosciences has a consensus target price of $87.30, suggesting a potential upside of 56.06%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Belite Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Belite Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.79

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Belite BioN/AN/A-$77.61M-$2.73N/A
MBX BiosciencesN/AN/A-$86.97M-$3.07N/A

Belite Bio's return on equity of -9.95% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Belite BioN/A -9.95% -9.76%
MBX Biosciences N/A -34.37%-32.72%

Belite Bio has a beta of -1.19, meaning that its stock price is 219% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, MBX Biosciences had 4 more articles in the media than Belite Bio. MarketBeat recorded 24 mentions for MBX Biosciences and 20 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.60 beat MBX Biosciences' score of 0.41 indicating that Belite Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Belite Bio
2 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MBX Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

MBX Biosciences beats Belite Bio on 8 of the 14 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

MetricMBX BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.71B$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E RatioN/A26.0432.9127.37
Price / SalesN/A7.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book5.585.144.403.70
Net Income-$86.97M$2.88B$3.52B$392.17M
7 Day Performance-1.74%-3.87%-5.34%-4.53%
1 Month Performance7.08%-3.96%-3.61%-5.86%
1 Year Performance114.28%-7.13%0.01%-7.78%

MBX Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
MBX Biosciences
2.9294 of 5 stars
$53.12
-5.0%
$87.30
+64.3%
+125.7%$2.71BN/AN/A63
CORT
Corcept Therapeutics
4.032 of 5 stars
$72.77
+1.6%
$139.50
+91.7%
-3.4%$7.96B$761.41M57.30730
AXSM
Axsome Therapeutics
3.526 of 5 stars
$132.37
+2.0%
$267.58
+102.1%
+1.4%$6.96B$865.27MN/A925
LNTH
Lantheus
2.4695 of 5 stars
$100.61
-0.1%
$107.44
+6.8%
+91.6%$6.57B$1.56B24.781,193
AMRX
Amneal Pharmaceuticals
4.107 of 5 stars
$20.14
+3.5%
$23.00
+14.2%
+83.7%$6.43B$3.20B47.958,500

Related Companies and Tools


This page (NASDAQ:MBX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners